Background
Pennsylvania’s approximately $1 billion opioid settlement fund—established following the Commonwealth’s 2022 suit against pharmaceutical manufacturers and distributors—is administered by the Board of Trustees of the Pennsylvania Opioid Misuse and Addiction Abatement Trust (Trust). Under the consent judgment, Trust funds may only be spent on purposes set forth in Exhibit E, a 15-page list divided into Schedule A (priority core abatement strategies) and Schedule B (a non-exhaustive list of treatment, prevention, and other strategies). The Board conducts retrospective review of expenditures to ensure Exhibit E compliance and can withhold future payments if it finds non-compliance. Subdivisions may challenge Board decisions by filing a “petition for specialized review” with the Commonwealth Court, which retains jurisdiction over the Trust until its dissolution.
Philadelphia created Program 9—the Kensington Resident Support Fund—to address root causes of addiction in Kensington, the neighborhood at the epicenter of Pennsylvania’s opioid epidemic. Program 9 included several sub-programs: home repair assistance, rent/mortgage relief, safety improvements to parks and schools, and small business support. Philadelphia argued that targeting the environmental and socioeconomic determinants of addiction in a high-risk area is precisely the kind of opioid abatement strategy contemplated by Exhibit E’s non-exhaustive Schedule B.
The Board initially rejected all of Program 9 as “general community development” not sufficiently tied to opioid use disorder. After a complaint process before the Trust’s Dispute Resolution Committee (DRC), the Board approved rent/mortgage relief and parks/school safety improvements but rejected home repair assistance and small business support. Its October 7, 2024 final decision was delivered by email without any explanation of which Exhibit E provision governed or why the two rejected sub-programs failed to qualify. Philadelphia filed a petition for specialized review.
The Court’s Holding
Remanded. A unanimous three-judge panel remanded to the Trust Board with instructions to issue a fully reasoned written decision within 30 days, without reaching the merits of whether home repair and small business support qualify under Exhibit E.
The court held that it could not conduct any appellate review because the Board’s email decision “does not reveal the underlying reasoning for why the program fell outside Exhibit E.” Drawing on the well-established principle that appellate courts require reasoned decisions suitable for review—analogizing to the Pa.R.A.P. 1925(a) requirement that trial courts state their reasons—the court found the Board’s bare-bones determination legally insufficient to sustain review.
The court specified in detail what the Board’s remand decision must contain: identification of the specific Exhibit E section(s) at issue and explanation of why the rejected programs do not qualify; specific findings of fact with citations to the record; credibility determinations; and definitions of any terms of art—such as “evidence-based” or “evidence-informed”—that the Board invokes to justify its denial. The court retained jurisdiction pending the Board’s compliance with the 30-day deadline and directed service of the opinion and order on the Attorney General.
Key Takeaways
- The PA Opioid Trust Board’s decisions rejecting county or subdivision programs must qualify as reasoned decisions—identifying the applicable Exhibit E provision, explaining why the program fails to qualify, providing specific findings of fact with record citations, credibility determinations, and definitions of any operative terms of art—before the Commonwealth Court can exercise appellate review.
- A bare-bones email rejection, without reasons, findings, or citations to the governing framework, is legally insufficient to sustain appellate scrutiny; the Commonwealth Court will remand rather than rule on the merits.
- Subdivisions challenging Trust Board funding denials should document the inadequacy of the Board’s written explanation as a threshold appellate argument, preserving the merits for post-remand review when the Board’s reasoning is finally on the record.
- The merits question—whether community development programs targeting addiction’s root causes (housing, economic stability, community safety) in high-risk neighborhoods qualify as opioid abatement expenditures under Exhibit E—remains open and will return to the court after the Board complies with the remand.
Why It Matters
For Philadelphia and other Pennsylvania municipalities relying on opioid settlement funds to address the downstream consequences of addiction in their hardest-hit neighborhoods, City of Philadelphia v. Opioid Trust provides a meaningful procedural foothold: Trust Board rejections that lack adequate reasoning can be successfully challenged for failure to provide a reviewable decision, creating space for a fuller record to develop on the merits. Counsel for subdivisions with pending or future Board disputes should insist on written, reasoned decisions at every stage of the Trust’s internal review process and appeal any bare-bones rejection to Commonwealth Court on adequacy-of-reasoning grounds if necessary.
For administrative law practitioners, the case extends the reasoned-decision requirement into the novel context of the Trust Board, which operates outside the traditional Commonwealth agency structure but remains subject to the Commonwealth Court’s continuing jurisdiction under the consent order. The practical implication is that Trust Board decisions—even those communicated informally—must meet the same baseline requirements for reasoned explanation that apply to other tribunals subject to Commonwealth Court review. The broader unresolved question—whether programs targeting root causes of addiction qualify under Exhibit E even without directly serving individuals with active opioid use disorder—will likely become one of the defining legal contests over how Pennsylvania’s billion-dollar opioid settlement is spent.